

Results of Annual General Meeting

20 November 2024

Melbourne, Australia, 20 November 2024: In accordance with Listing Rule 3.13.2 and section 251AA of the *Corporations Act 2001* (Cth), the results of the resolutions put to shareholders at today's 4DMedical Limited Annual General Meeting are included in the attached document. All resolutions were carried by the requisite majorities.

In respect of Resolution 2 (Remuneration Report), holders of 8,988,736 shares (representing 2.2% of the total of 411,227,914 shares on issue) voted against the resolution. As this represents more than 25% of the votes cast against the resolution, this constitutes a first strike for the purposes of the *Corporations Act 2001* (Cth).

–ENDS–

Authorised by the 4DMedical Company Secretary.

Contacts

Corporate

Chief Financial Officer
Simon Glover
sglover@4dmedical.com

Administration

Company Secretary
Naomi Lawrie
companysecretary@4dmedical.com

Media Enquiries

4dmedia@4dmedical.com

About 4DMedical

4DMedical Limited (ASX:4DX) is a global medical technology company that has created a step change in the capacity to accurately and quickly understand the lung function of patients with respiratory diseases.

Through its flagship patented XV Technology®, 4DMedical enables physicians to understand regional airflow in the lungs and identify respiratory deficiencies earlier and with greater sensitivity as they breathe. This technology powers 4DMedical's FDA-cleared XV Lung Ventilation Analysis Software (XV LVAS®) – the first modality to dynamically quantify ventilation throughout the lungs, and its Computed Tomography-enabled counterpart software, CT LVAS™.

XV LVAS® and CT LVAS™ reports are prepared using 4DMedical's Software as a Service delivery model using existing hospital imaging equipment or the Company's revolutionary XV Scanner.

In December 2023, 4DMedical acquired Imbio, a leader in artificial intelligence medical imaging solutions for chronic lung and cardiothoracic diseases. Imbio's regulatory-cleared solutions transform the way patients are discovered, diagnosed, and treated, enabling physician productivity and more personalised care for patients.

To learn more, please visit www.4dmedical.com and www.imbio.com

Melbourne

Level 7 Melbourne Connect
700 Swanston Street
Carlton VIC 3053
Tel: +61 (3) 9545 5940

Los Angeles

21255 Burbank Boulevard
Suite 120
Woodland Hills CA 91367
Tel: +1 (818) 403-8490

4DMedical Limited
ABN: 31 161 684 831
Email: info@4dmedical.com
www.4dmedical.com

ANNUAL GENERAL MEETING
Wednesday, 20 November 2024

As required by section 251AA(2) of the Corporations Act 2001 (Commonwealth) the following statistics are provided in respect of each resolution on the agenda.

Resolution Voted on at the meeting			Proxy Votes (as at proxy close)				Total votes cast in the poll (where applicable)			
No	Short Description	Strike Y/N/NA	For	Against	Discretionary (open votes)	Abstain	For	Against	Abstain **	Result
2	REMUNERATION REPORT	Y	15,628,689 58.33%	8,141,764 30.38%	3,024,919 11.29%	981,043	19,089,225 67.99%	8,988,736 32.01%	981,043	Carried
3	RE-ELECTION OF DIRECTOR, DR ROBERT A. FIGLIN	NA	89,116,834 96.28%	289,674 0.31%	3,157,374 3.41%	128,082	93,400,580 98.87%	1,068,999 1.13%	128,082	Carried
4A	APPROVAL FOR THE PROPOSED ISSUE OF OPTIONS TO DIRECTOR - MS LIL BIANCHI	NA	18,114,801 66.07%	6,287,208 22.93%	3,013,691 10.99%	360,715	21,631,756 75.38%	7,066,533 24.62%	360,715	Carried
4B	APPROVAL FOR THE PROPOSED ISSUE OF OPTIONS TO DIRECTOR MR JOHN LIVINGSTON	NA	15,614,292 56.94%	8,798,464 32.09%	3,008,691 10.97%	354,968	19,126,247 66.63%	9,577,789 33.37%	354,968	Carried
4C	APPROVAL FOR THE PROPOSED ISSUE OF OPTIONS TO DIRECTOR MR JULIAN SUTTON	NA	15,541,685 56.69%	8,855,324 32.30%	3,018,691 11.01%	360,715	19,063,640 66.43%	9,634,649 33.57%	360,715	Carried
4D	APPROVAL FOR THE PROPOSED ISSUE OF RESTRICTED STOCK UNITS TO DIRECTOR DR ROBERT A. FIGLIN	NA	18,091,940 66.01%	6,295,629 22.97%	3,018,691 11.01%	370,155	22,143,697 75.79%	7,074,954 24.21%	370,155	Carried
4E	APPROVAL FOR THE PROPOSED ISSUE OF RESTRICTED STOCK UNITS TO DIRECTOR DR GERALDINE MCGINTY	NA	20,467,840 74.79%	3,879,729 14.18%	3,018,691 11.03%	410,155	23,989,795 83.74%	4,659,054 16.26%	410,155	Carried
5A	APPROVAL FOR THE PROPOSED ISSUE OF OPTIONS TO DIRECTOR IN LIEU OF BASE DIRECTORS FEES MS LIL BIANCHI	NA	22,101,568 80.57%	2,225,824 8.11%	3,104,109 11.32%	344,914	25,708,941 89.53%	3,005,149 10.47%	344,914	Carried
5B	APPROVAL FOR THE PROPOSED ISSUE OF RESTRICTED STOCK UNITS TO DIRECTOR IN LIEU OF BASE DIRECTORS FEES - DR GERALDINE MCGINTY	NA	22,123,936 80.93%	2,178,737 7.97%	3,033,410 11.10%	440,332	25,660,610 89.66%	2,958,062 10.34%	440,332	Carried
6	GRANT OF OPTIONS TO MANAGING DIRECTOR AND CEO	NA	16,940,616 61.69%	7,495,055 27.30%	3,023,663 11.01%	317,081	20,399,896 71.11%	8,288,573 28.89%	370,535	Carried

ANNUAL GENERAL MEETING
Wednesday, 20 November, 2024

As required by section 251AA(2) of the Corporations Act 2001 (Commonwealth) the following statistics are provided in respect of each resolution on the agenda.

Resolution Voted on at the meeting			Proxy Votes (as at proxy close)				Total votes cast in the poll (where applicable)			
No	Short Description	Strike Y/N/NA	For	Against	Discretionary (open votes)	Abstain	For	Against	Abstain **	Result
7	APPROVAL OF 10% PLACEMENT CAPACITY	NA	79,963,161 86.55%	9,288,824 10.05%	3,137,548 3.40%	302,431	84,227,081 89.32%	10,068,149 10.68%	302,431	Carried
8	RATIFICATION OF PRIOR ISSUE OF SHARES	NA	88,527,154 95.89%	643,831 0.70%	3,147,548 3.41%	373,431	92,801,074 98.49%	1,423,156 1.51%	373,431	Carried

** - Note that votes relating to a person who abstains on an item are not counted in determining whether or not the required majority of votes were cast for or against that item

* In relation to Resolution 2 Remuneration Report, as more than 25% of the votes were cast against the resolution, this constitutes a first strike for the purposes of the Corporations Act 2001 (Cth).